TCL Archive In Brief: VP-16 NDA Approved By FDA Only For Refractory Testicular Cancer; Removed From Group C List December 2, 1983
TCL Archive NCI funds 17 EDRN biomarker labs. Bush signs omnibus funding legislation. December 10, 2004
TCL Archive Phase III Trial Finds Cabazitaxel Increases Survival Of Advanced Prostate Cancer March 26, 2010